Martine Zimmermann
Director/Board Member bij INVENTIVA
Vermogen: 167 034 $ op 31-03-2024
Profiel
Martine Zimmermann is an Independent Director at Ligand Pharmaceuticals, Inc. and Inventiva SA. She is also the SVP and Head of Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals, Inc. Previously, she worked as a Director at Caelum Biosciences, Inc. and as the Senior VP and Head of Global Regulatory Affairs at Alexion Pharmaceuticals, Inc. She holds a doctorate degree from both the University of Strasbourg and Louis Pasteur University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 22-09-2023 | 2 285 ( 0.01% ) | 167 034 $ | 31-03-2024 |
Actieve functies van Martine Zimmermann
| Bedrijven | Functie | Begin |
|---|---|---|
| INVENTIVA | Director/Board Member | 16-04-2021 |
| LIGAND PHARMACEUTICALS INCORPORATED | Director/Board Member | 26-09-2023 |
| Ipsen Biopharmaceuticals, Inc. | General Counsel | - |
Eerdere bekende functies van Martine Zimmermann
| Bedrijven | Functie | Einde |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | General Counsel | 01-02-2023 |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Director/Board Member | 01-01-2021 |
Opleiding van Martine Zimmermann
| University of Strasbourg | Doctorate Degree |
| Louis Pasteur University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| INVENTIVA | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
| Ipsen Biopharmaceuticals, Inc. | |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Health Technology |
